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ABSTRACT 
Currently available tumor markers for hepatocellular carcinoma (HCC) are α-fetoprotein 
(AFP) ， lens culinaris agglutinin-reactive AFP (AFP-L3)， and des-r-carboxy prothrombin 
(DCP). However， their diagnostic potential cannot surpass abdominal ultrasonography (US) 
as modalities to detect small HCC at early stage， leading that they may delay its diagnosis. 
We here introduce a newly developed quantitative detection method for serum hTERT 
mRNA， which has a clinical significance in HCC diagnosis. In 64 patients with HCC， 20 
with liver cirrhosis， 20 with chronic hepatitis， and 50 healthy individuals， we measured se-
rum hTERT mRNA by using the newly developed real-time quantitative RT-PCR with 
SYBR Green I. Briefly， we examined its sensitivity and specificity in HCC diagnosis， clini-
cal significance in comparison with other tumor markers， and its correlations with the clini-
cal parameters by using multivariate analyses and Friedman test. Serum hTERT mRNA 
showed higher values in patients with 五CCthan those with chronic liver diseases. hTERT 
mRNA expression was demonstrated to be independently correlated with clinical parameters 
such as tumor size， number and differentiation degree (P<O.OOl， each). hTERT mRNA 
expression independently correlated with clinical parameters such as differentiation degree 
(P<O.OOl). The sensitivity/specificity of hTERT mRNA in HCC diagnosis showed 88.2%/ 
70.0%. hTERT mRNA proved to be expectedly superior to AFP mRNA， AFP and DCP in 
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HCC diagnosis. Importantly， hTERT mRNA in serum was correlated with that in耳CCtis-
sue. Thus， we report that serum hTERT mRNA is a novel and available marker for HCC 
detection. (Accepted on November 16， 2006) 










































































































































により， SYBR Green 1を用いて，再現性を確認
して実行された.当手法のhTERTmRNA及び、






0.0001， P < 0.0001， P < 0.0001; AFPでP= 






相関していた(各P< 0.05， P < 0.01， P < 


















































cut-off point for hTERT mRNA 
.・M ・， DCP 
cut-off point for DCP 
AFP mRr¥JA 
cut-off point for AFP mRNA 
鳳・R・AFP ・cut-offpoint for AFP 

























NL:正常肝(健常者).OL:他の肝病変を有する患者， CH:慢性肝炎患者， LC:肝硬変患者， HCC:肝癌患者(図l
-A).散布図は血清中hTERTmRNA{lli!と肝癌組織中hTERTmRNA値との有意な相関が10症例について示して
いる.Paired t検定(P= 0.01)とSpearman相関検定(P= 0.017)で解析した(国1-B).hTERT mRNAとAFP
mRNAfこ関するReceiveroperator characteristic (ROC) curve解析を示している.その出線は定量測定値を統計
解析ソフトSPSS13.0で解析かっ描回したものである.The dotted 1ine， bold dotted line， solid line， and bold solid 
















Multivariate analyses and Freidman test 
hTERTmRNA AFPmRNA AFP (-L3) DCP 
Clinical parameters # ofpatient ρ D ρ D 
Age mean:59 years old (range 22 to 83 ) 0.408 0.798 0.681 (0.690) 0.981 
Gender M 94 0.761 0.089 0.412 (0.408) 0.380 
F 60 









Albumin (g/ dl) 0.018 0.340 0.540 (0.601) 0.001 
Total bilirubin (mg/ dl) 0.928 0.693 0.111 (0.432) 0.933 
Alanine aminotransferase (IU /1) 0.538 0.149 0.001 (0.001) 0.978 
Chi1d-Pugh Scale A 21 O. 136 0.573 0.373 (0.020) 0.001 
B 44 
C 5 
AFP (ng/ml) 0.201 0.319 
AFP-L3 (%) O. 123 0.425 
DCP (mA U / ml) 0.854 0.651 
Size of tumor (mm) < 20 18 <0.001 0.061 0.358 (0.001) 0.258 
20~30 26 
> 30 20 
Number of tumors 10 0.123 0.200 (0.012) 0.086 
2 27 
ミ~ 3 27 




U ndifferen tia ted 
Only hTERT mRNA correlated with albumin， tumor size， tumor number， and differentiation degree of 
tumor independently during the progression from chronic liver diseases to HCC. HBV: hepatitis B vi-
rus， HCV: hepatitis C virus， NBNC: non-HBV non-HCV， AH: adenomatous hyperplasia. 















p va1ue PPV/NPV 
0.002 0.812/0.389 
0.304 0.778/0.277 
< 0.001 0.852/0.405 
< 0.001 0.695/0.741 
< 0.001 0.862/0.870 
CH/LCー )-HCC LC -)-HCC 










< 0.001 < 0.001 
(表2-A) HCCの各腫蕩マーカーの感度/特異度とPPV/NPVを示す PPV:posi-
tive predictive va1ue， NPV: negative predictive va1ue. (表2-B) 肝発癌過程での
各腫蕩マーカーにおける統計上の有意差を示す.
AFP値， AFP-L3 (%)が腫蕩数と有意な相関を
示し(各P< 0.05)，腫場径を<20 mm， 20-














tive va1ue (PPV) / negative predictive va1ue 
(NPV)は0.862/0.870であった.またAFP


























1. AnゅρJ仰 tionfor 1仰 lignancies
a) A dia停losisof malignancies 
Lung cancer 
Adenocarcinoma 
Squamous cel carcinoma 
Small cel lung carcinoma 


































b) A Comparison of hTERT mRNA with PET 
in periodic medical examination for cancer 
c) An evaluation of the induction or effect of 
anticancer therapy 
2. An aPPlication for other diseases 
a) 1nflammatory diseases 
Fulminant hepatitis 
Autoimmune disease 
N onalcoholic steatohepatitis 
b) Ischemic diseases 
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